Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are ...

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

In a challenging market environment, Immunic, Inc. (NASDAQ:IMUX) stock has recorded a new 52-week low, dipping to $0.92. The biopharmaceutical company, which focuses on developing treatments for ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...

Analysts at William Blair issued their FY2026 EPS estimates for shares of Immunic in a research note issued to investors on ...

Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million.

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

Short interest in Immunic Inc (NASDAQ:IMUX) decreased during the last reporting period, falling from 2.55M to 2.40M. This put 2.69% of the company's publicly available shares short. Short interest ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...